NCT00019539 2024-03-04
Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Completed
Clinical Trials
34 trialsNCT00020046 2023-10-31
Docetaxel With or Without Thalidomide in Treating Patients With Metastatic Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00025220 2019-07-23
Thalidomide in Treating Patients With Recurrent or Persistent Cancer of the Uterus
National Cancer Institute (NCI)
Phase 2 Completed
NCT00089609 2018-04-20
Docetaxel, Thalidomide, Prednisone, and Bevacizumab to Treat Metastatic Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00089544 2018-04-13
Preoperative Thalidomide With Radiation Therapy For Patients With Low-Grade Primary Soft Tissue Sarcoma or Thalidomide With Radiation Therapy and Chemotherapy For Patients With High-Grade or Intermediate-Grade Primary Soft Tissue Sarcoma of the Arm, Leg, or Body Wall
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00019747 2015-10-28
Surgery With or Without Thalidomide in Treating Patients With Recurrent or Metastatic Colorectal Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00033709 2014-01-06
Temozolomide and Thalidomide in Treating Patients With Metastatic, Locally Advanced, or Unresectable Leiomyosarcoma
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00006226 2013-10-08
Thalidomide in Treating Patients With Relapsed Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT00276705 2013-09-17
Combination Chemotherapy and Thalidomide in Treating Younger Patients Undergoing Surgery For Newly Diagnosed Liver Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00004876 2013-08-26
Carboplatin With or Without Thalidomide in Treating Patients With Ovarian Epithelial Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00958854 2013-08-26
Fludarabine, Cyclophosphamide, and Thalidomide in Treating Patients With Angioimmunoblastic T-Cell Lymphoma
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00019123 2013-08-16
Thalidomide in Treating Patients With HIV-Associated Kaposi's Sarcoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00027664 2013-08-07
Interferon Alfa With or Without Thalidomide in Treating Patients With Metastatic Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00058487 2013-07-18
Epirubicin and Thalidomide in Treating Patients With Liver Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00112879 2013-07-10
Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT00053001 2013-06-26
Thalidomide and Epoetin Alfa in Treating Anemia in Patients With Myelodysplastic Syndrome
National Cancer Institute (NCI)
Phase 2 Completed
NCT00022607 2013-06-24
Bevacizumab With or Without Thalidomide in Treating Patients With Relapsed or Refractory Multiple Myeloma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00026520 2013-06-24
Interferon Alfa and Thalidomide in Treating Patients With Stage IV Melanoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00006005 2013-06-21
Thalidomide in Treating Patients With Gynecologic Sarcomas
National Cancer Institute (NCI)
Phase 2 Completed
NCT00009984 2013-06-06
Thalidomide With or Without Fludarabine in Treating Patients With Hematologic Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00046826 2013-04-04
Docetaxel, Estramustine, and Thalidomide in Treating Patients With Prostate Cancer Previously Treated With Hormone Therapy
National Cancer Institute (NCI)
Phase 2 Completed
NCT00017316 2013-02-11
Thalidomide and SU5416 in Treating Patients With Metastatic Melanoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00003850 2013-02-08
Thalidomide in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00015912 2013-01-25
Interferon Alfa Plus Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00015990 2013-01-24
Thalidomide in Treating Patients With Myelodysplastic Syndrome
National Cancer Institute (NCI)
Phase 2 Completed
NCT00025467 2013-01-24
Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00072163 2013-01-17
Temozolomide and Thalidomide in Treating Patients With Brain Metastases Secondary to Melanoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00083005 2012-03-15
Docetaxel, Estramustine, and Thalidomide in Treating Patients With Androgen-Independent Metastatic Adenocarcinoma of the Prostate
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00047879 2011-10-26
Phase II Trial of Peginterferon Alpha-2b and Thalidomide in Adults With Recurrent Gliomas
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00438841 2009-03-13
Bortezomib, Cyclophosphamide, Dexamethasone, and Thalidomide in Treating Patients With Newly Diagnosed, Previously Untreated Multiple Myeloma
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00001446 2008-03-04
A Randomized Phase II Study of Oral Thalidomide in Patients With Hormone-Refractory Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00001475 2008-03-04
Home Treatment of HIV-Infected Patients With Interleukin-2 With or Without a Tumor Necrosis Factor Antagonist
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00001524 2008-03-04
Thalidomide to Treat Oral Lesions in HIV-Infected Patients
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00006200 2005-06-24
Thalidomide and Dacarbazine for Metastatic Melanoma
National Center for Research Resources (NCRR)
Phase 2 Unknown